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Mutations in the X-linked cyclin-dependent kinase-like 5
(CDKL5) gene have been identified in patients with Rett syn-
drome, West syndrome, and X-linked infantile spasms sharing
the common features of generally intractable early seizures and
mental retardation. Disease-causing mutations are distributed
in both the catalytic domain and in the largeCOOHterminus. In
this report, we examine the functional consequences of some
Rett mutations of CDKL5 together with some synthetically
designed derivatives useful to underline the functional domains
of the protein. The mutated CDKL5 derivatives have been sub-
jected to in vitro kinase assays and analyzed for phosphorylation
of the TEY (Thr-Glu-Tyr)motif within the activation loop, their
subcellular localization, and the capacity of CDKL5 to interact
with itself. Whereas wild-type CDKL5 autophosphorylates and
mediates the phosphorylation of the methyl-CpG-binding pro-
tein 2 (MeCP2) in vitro, Rett-mutated proteins show both
impaired and increased catalytic activity suggesting that a tight
regulation of CDKL5 is required for correct brain functions.
Furthermore, we show that CDKL5 can self-associate andmedi-
ate the phosphorylation of its own TEY (Thr-Glu-Tyr) motif.
Eventually, we show that the COOH terminus regulates CDKL5
properties; in particular, it negatively influences the catalytic
activity and is required for its proper sub-nuclear localization.
We propose a model in which CDKL5 phosphorylation is
required for its entrance into the nucleus whereas a portion of
theCOOH-terminal domain is responsible for a stable residency
in this cellular compartment probably through protein-protein
interactions.
X-linked cyclin-dependent kinase-like 5 (CDKL5,3 previ-
ously named STK9) was originally identified in a transcriptional
mapping project focused on the human chromosome Xp22.3-
p21.3, spanning a region critical for several diseases. Expression
studies demonstrated that CDKL5 was transcribed in several
tissues, including brain (1). However, the possible link between
CDKL5 and human diseases was drawn only few years later
when balanced translocating events disrupting the gene were
identified in two female patients affected by severe infantile
spasms and mental retardation (2). Retrospectively, a previous
publication had identified a large deletion involvingCDKL5 in a
male patient with X-linked retinoschisis and seizure (3); it has
recently been hypothesized that retinoschisis is due to deletion
of the XLRS1 gene, whereas epilepsy is caused by truncation of
at least the last exon of CDKL5 (2). The importance of CDKL5
in early onset seizures and severe mental retardation in females
has been further reinforced by five recent reports linkingmuta-
tions in CDKL5 to patients with Rett syndrome but only in
those affected by a variant form characterized by seizure onset
before 6 months of age (4–8). Very recently the frequency of
CDKL5 mutations in patients affected by infantile spasms or
early onset epilepsy of unknown cause has been investigated.
The identification of several novel likely pathogenic mutations
led the authors to propose thatCDKL5mutations in females are
a significant cause of severe mental retardation and of forms of
early epilepsy that are generally intractable (9). Despite the
clear involvement of CDKL5 in human health, this protein
remains almost completely uncharacterized; presently, we are
missing its functions in the nervous system aswell as themolec-
ular consequences of its pathogenic mutations.
Given its amino acids sequence, CDKL5 was supposed to be
a proline-directed serine/threonine kinase sharing homology
with members of the mitogen-activated protein (MAP) kinase
and cyclin-dependent kinase (CDK) families (1). Moreover, the
similar Rett phenotypes in patients carrying mutations in the
gene coding for the methyl-CpG-binding protein 2 (MECP2)
and CDKL5, together with recent reports demonstrating the
importance of MeCP2 phosphorylation for selective binding to
DNA (10), opened the possibility that the two proteins might
operate in a common developmental pathway. In favor of this
hypothesis, we have recently shown that generally the two
genes show spatial and temporal overlapping expression pat-
tern that is simultaneously activated by neural maturation and
synaptogenesis. Moreover, we demonstrated that CDKL5 and
MeCP2 interact and that immunopurified CDKL5 leads,
directly or indirectly, to the phosphorylation of the methyl-
binding protein (8). The interaction between MeCP2 and
CDKL5 has also been confirmed by Lin and colleagues; how-
ever, the failure in reproducing theMeCP2 phosphorylation led
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the authors to propose that MeCP2 might target CDKL5 to
DNA-binding complexes containing a different functional sub-
strate of the enzyme (11).
Integrating all data so far available, the emerging picture is
that, in fact, CDKL5 and MeCP2 work in common molecular
pathways. However, the demonstration that CDKL5mutations
are an important etiological factor for neurodevelopmental dis-
orders in addition to Rett syndrome (9), together with our pre-
vious expression studies showing that in some specific cerebel-
lar domains the two genes are independently regulated (8),
suggest that the kinasemight also have functions not connected
to the methyl-binding protein.
In this study we characterize several CDKL5-mutated deriv-
atives, including some of those identified in Rett patients.
Phosphorylation assays performed with the wild-type pro-
tein confirm its capability to mediate the modification of
MeCP2 in vitro, whereas Rett missense mutations within the
conserved catalytic domain abrogate or significantly impair the
enzymatic activity. Interestingly, none of these mutants main-
tains the capability to influence the phosphorylation status of
the methyl-binding protein. Frameshift mutations, which gen-
erate truncated proteins in patients, have been found both in
the amino- and carboxyl-terminal regions of CDKL5. We
therefore analyzed two derivatives interrupting the unusually
large COOH-terminal region. Our results suggest that the
COOH terminus of the protein has regulatory functions that
can influence either the catalytic activity or the subcellular
localization.We conclude that both a change inCDKL5 activity
and its mislocalization can be responsible for the onset of neu-
rodevelopmental disorders and believe that these studies
should help in drawing some speculations on theCDKL5muta-
tion genotype/phenotype correlation.
EXPERIMENTAL PROCEDURES
Plasmid Construction—Recombinant hMeCP2E2 was pro-
duced from the pTYB1-hMeCP2 vector containing the entire
cDNA of MeCP2 (486 amino acids) cloned into the NdeI and
XhoI sites of pTYB1 (NewEnglandBiolabs) generating a chitin-
binding fusion protein. Recombinant hCDKL5 encompassing
amino acids 301–751 for immunizing rabbits was produced as a
chitin-binding fusion protein from pTYB1-CDKL5301–751. The
corresponding cDNA was generated by PCR and cloned into
the NdeI and SapI sites of pTYB1.
pGFP-CDKL5 contains the entire cDNA of hCDKL5 (1030
amino acids) generated by PCR and cloned into the BspEI-BamHI
sites of pEGFP-C1 (Clontech). Subsequently, an extra BamHI site,
allowing the excision of theCDKL5 cDNAwith BamHI, has been
introduced downstream of the BspEI site. The C152F, R175S,
andK42R derivatives were generated by site-directedmutagen-
esis using the QuikChange! site-directed mutagenesis kit
(Stratagene). !N contains amino acids 298–1030, !781 amino
acids 1–780, and !525 1–524. The analogous FLAG-CDKL5
derivatives (NH2-terminal FLAG-tag) were expressed from the
pCMV-Tag-2B vector (Stratagene) into which the cDNAswere
cloned into BamHI.
All PCR-generated constructs were verified by sequencing.
Antibodies—A rabbit anti-CDKL5 anti-serum (Covance
Research Products Inc.) was raised against hCDKL5 amino
acids 301–751 expressed in Escherichia coli as a fusion protein
containing a chitin-binding domain that was eliminated during
the purification procedure.
For immunopurification and Western blots the following
antibodies were used: monoclonal anti-FLAG (Sigma), poly-
clonal anti-MeCP2 (Sigma),monoclonal anti-GFP (Roche), and
polyclonal anti-phospho-p44/42 MAP kinase antibody (Cell
Signaling).
Recombinant Protein Purification—Recombinant full-length
hMeCP2E2 and hCDKL5 amino acids 301–751 were expressed
in E. coli ER2566 and induced with 0.5 mM isopropyl
!-D-thiogalactopyranoside at 30 °C for 5 h. Following induc-
tion, extracts were prepared by resuspending the bacteria in
lysis buffer (750 mM NaCl, 20 mM Tris-HCl, pH 8.0, 1 mM
EDTA, 0.1% Triton X-100, protease inhibitor mixture (Sigma
P4380)) and sonicated. Following centrifugation at 40,000 rpm
for 10 min, the cleared lysate was applied to chitin-agarose
(New England Biolabs Inc.) pre-equilibrated with lysis buffer,
after which the columnwas washed with 20 column volumes of
lysis buffer. Fusion proteins were cleaved on the column over-
night by incubation with lysis buffer containing 50 mM dithio-
threitol. Eluted fractions containing the bulk of MeCP2 or
CDKL5 were pooled. Recombinant purified MeCP2 was dia-
lyzed against the kinase buffer used in the phosphorylation
assays whereas CDKL5 was dialyzed against phosphate-buff-
ered saline.
Cell Culture and Transfection—The human embryo-derived
kidney cell line HEK293 and mouse fibroblasts, NIH3T3, were
maintained in Dulbecco’s modified Eagle’s medium supple-
mented with 10% fetal calf serum at 37 °C with 5% CO2. Tran-
sient transfections were performed with calcium phosphate or
Lipofectamine 2000 (Invitrogen) according to the manufactur-
ers instructions and cells harvested 20–36 h post-transfection.
In Vitro Phosphorylation Assays—For the detection of
CDKL5 autophosphorylation, FLAG-CDKL5 or its mutated
derivatives were immunoprecipitated from overexpressing
HEK293 cells and incubated with ["-33P]ATP. Briefly, total cell
extracts were prepared from"106 transiently transfected cells
with high salt lysis buffer (50 mM Tris-HCl, pH 8.0, 500 mM
NaCl, 0.1% Nonidet P-40, 1 mM dithiothreitol, phenylmethyl-
sulfonyl fluoride, and protease inhibitor mixture (Sigma
P4380)). Equal amounts of protein extract were precleared for
1 hwith 20#l of 100%mouse IgG-agarose beads at 4 °C; 40#l of
100% EZviewRed Anti-FLAG M2 Affinity gel (Sigma) was
added to the cleared extract and themixture incubated for 2 h at
4 °C. Immunocomplexes were collected by centrifugation,
washed five timeswith the above lysis buffer containing 700mM
NaCl, and 85% of the pellet was used in kinase assays as
described previously (8).
For the phosphorylation of MeCP2, 3 #g of recombinant
hMeCP2E2 were added to the FLAG-CDKL5 pellet resus-
pended in kinase buffer and subjected to phosphorylation as
previously described (8). 85% of the labeled proteins were sep-
arated by SDS-PAGE, visualized by autoradiography or quanti-
tated by PhosphorImager analysis (GE Healthcare). To detect
the immunopurified CDKL5 derivatives and MeCP2, 15% of
the immunocomplexes were assayed byWestern blot. A Kodak
Image Station 2000R was used to quantitate the signals in the
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Western blot. CDKL5 autophosphorylation activity was
expressed as the ratio between incorporated 33P and the corre-
sponding immunoreactive signal.
Fractionated Extracts and Immunoprecipitation Experi-
ments—For fractionation experiments, 5 # 105 HEK293 were
collected 36 h after transfection, washed twice with phosphate-
buffered saline, and lysed in hypotonic lysis buffer (20 mM
Hepes, pH 8.0, 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA) sup-
plemented with phosphatase and protease inhibitors (1 mM
Na3VO4, 1mM dithiothreitol, 5 mMNaF, phenylmethylsulfonyl
fluoride, and protease inhibitor mixture) by incubation on ice
for 45 min. After centrifugation at 500# g for 5 min the super-
natant was kept as the cytosolic fraction. The pelleted nuclei
were washed once in the phosphate-buffered saline, resus-
pended in nuclear lysis buffer (10 mM Hepes, pH 8.0, 1.5 mM
MgCl2, 1 M KCl, 0.2 mM EDTA, 1%Nonidet P-40, 25% glycerol)
supplemented with the above mentioned inhibitors, incubated
for 30 min on ice, and subsequently sonicated to destroy
genomic DNA. Cellular debris were removed by centrifugation
for 30 min at 18,000 # g at 4 °C and the protein extracts ana-
lyzed by immunoblotting.
For coimmunoprecipitation experiments, 1 # 106 HEK293
cells coexpressing GFP-CDKL5 and FLAG-CDKL5 derivatives
were collected, resuspended in lysis buffer (50 mM Tris-HCl,
pH 8.0, 150 mM NaCl, 1% Triton, 2 mM EDTA, 10% glycerol)
supplemented with protease and phophatase inhibitors (1 mM
Na3VO4, 1mM dithiothreitol, 5 mMNaF, phenylmethylsulfonyl
fluoride, and protease inhibitormixture), sonicated, and centri-
fuged for 15 min at 18,000# g at 4 °C. The extract was cleared
and immunoprecipitated with an anti-FLAG resin as described
for phophorylation assays and the immunocomplexes washed
four times with the lysis buffer and analyzed by Western blot.
For the phospho-TEY assay, total extracts from 1# 106 tran-
siently transfected HEK293 cells were prepared as for coimmu-
noprecipitation experiments and extracted proteins purified
with either anti-FLAG resin as described above or with anti-
GFP antibodies. The extracts were incubated for 1 h with the
primary antibody, after which protein-G-Sepharose (KPL) was
added, the mixture incubated for 2 h and immunocomplexes
washed four times with the lysis buffer and analyzed by West-
ern blot.
Immunofluorescence—Mouse fibroblasts, NIH3T3, were
seeded on gelatin-coated glass coverslips and transiently trans-
fected with Lipofectamine 2000 (Invitrogen). 20 h post-trans-
fection the cells were fixed with 4% paraformaldehyde, stained
with Hoechst 33258 (Sigma) and analyzed with an Olympus
BX51 fluorescence microscope.
RESULTS
Disease-causing Mutations in CDKL5—Mutations in the
CDKL5 gene have recently been identified in patients suffering
from Rett syndrome, West syndrome, and infantile spasms (2,
4–9), which share the common features of early-onset seizures
andmental retardation, suggesting an important role ofCDKL5
in the nervous system. CDKL5 is a large protein of 1030 amino
acids with an estimated molecular mass of 116 kDa (Fig. 1A)
containing a conserved serine-threonine kinase domain within
its NH2 terminus and a large COOH-terminal region to which
no function has yet been assigned (1). Even if the number of
patients is still rather limited, themutations identified so far are
located in various regions of the protein. Four missense muta-
tions have been identified in the catalytic domain of the protein;
among these, the C152F and R175S mutations have been sug-
gested to interfere with phosphotransfer and either kinase acti-
vation or substrate specificity, respectively (4, 11). Frameshift
mutations causing the premature deletion of the protein have
been found both in the catalytic domain and in a region span-
ning almost 400 amino acids of the very carboxyl terminus,
suggesting an important role of this region for CDKL5 func-
tions. To map the functional domains of the protein and reveal
how its activities are regulated, we decided to analyze various
CDKL5 derivatives in functional assays; besides performing
in vitro phosphorylation assays, we also assayed the subcellular
localization as well as the capacity of CDKL5 to interact with
itself. We chose to characterize the two Rett derivatives C152F
and R175S mutated within the catalytic domain as well as two
COOH-terminally truncated proteins (Fig. 1B). Whereas the
!781 derivative carries a 249 amino acids deletion identified in
a Rett patient, the synthetic !525 derivative is deleted of most
FIGURE 1. Schematic illustration of CDKL5 with disease-causing muta-
tions within the open reading frame. A, full-length human CDKL5 is 1030
amino acids long and containswithin the catalytic domain (light gray box) the
ATP-binding site (dark gray box), the serine-threonine kinase active site (black
box), and the conserved TEY motif (dotted line). A putative signal peptidase I
serine active site is present in the carboxyl terminal region (striped box). Four
PxxP sequences, constituting possible binding sites for Src homology 3-con-
taining proteins, are indicated with arrowheads. Disease-causing mutations
are shown with missense mutations on the top and frameshift mutations on
the bottom. The black bar above the COOH terminus of CDKL5 indicates the
region deleted in some retinoschisis patients with epilepsy. Rett causing
mutations are indicated with an asterisk. B, schematic representation of the
utilized CDKL5 derivatives fused to either FLAG or GFP. The disease-causing
mutations are named according to Den Dunnen et al. (12).
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of the COOH terminus and lacks the three PxxP sites within
this region, which constitutes binding sites for Src homology
3-domain proteins (11). Finally, as a control, we also analyzed a
CDKL5derivative lacking the entire kinase domain (!N) aswell
as a kinase-dead mutant, K42R, that has been mutated in the
highly conserved ATP-binding site (11, 13).
Rett Mutations in the Catalytic Domain Influences CDKL5
Catalytic Activity—The catalytic activity of CDKL5 has been
reported to be involved in its autophosphorylation in vitro (8,
11). We decided to analyze the various mutated derivatives for
autophosphorylation activity and to this aim the mutated pro-
teins carrying an NH2-terminal FLAG epitope were immuno-
purified from overexpressing mammalian cells and the exten-
sively washed pellet incubated with ["-33P]ATP. 85% of the
labeled proteins were separated by SDS-PAGE and visualized
by autoradiography (Fig. 2A, upper panel). To normalize for the
amount of protein used in these assays, the remaining 15% of
the labeled proteins were analyzed by Western blot using anti-
CDKL5 antibodies (Fig. 2A, lower panel). As shown in the auto-
radiogram in Fig. 2A, a band corresponding to wild-type
CDKL5 is present (lane 2); the absence of this signal in the
reaction with FLAG alone (lane 1) shows that the signal is spe-
cific for CDKL5. Furthermore, the absence of phosphorylation
of the twoCDKL5 derivatives lacking catalytic activity allows us
to conclude that no other kinase co-purifying with CDKL5
causes its post-translationalmodification. In fact, the lanes cor-
responding to!NandK42R are devoid of signals (lanes 3 and 7,
respectively). The C152F mutation precedes the conserved
DFG triplet involved in phosphoryl transfer and has accord-
ingly been predicted to interfere with the catalytic activity of
CDKL5 (4, 11, 13). In agreement with this hypothesis, we
observe that the C152F derivative is completely devoid of
autophosphorylation activity (lane 5). Conversely, the R175S
mutant, which is located downstream of the dual phosphoryla-
tion site within the activation loop (4, 13), maintains the capac-
ity of autophosphorylation even if it appears to have a reduced
activity (lane 6), corresponding to "55% of wild-type CDKL5
(Fig. 2B) (henceforth referred to as hypomorphic mutant).
Deletion of the last 249 amino acids confers a higher autophos-
phorylation activity to CDKL5; in fact, the !781 derivative
appears"1.5-fold more active than the wild-type protein (Fig.
2A, lane 4, and Fig. 2B). Lin et al. (11) have recently proposed
that the COOH terminus of CDKL5 has a negative regulatory
function since a derivative of the kinase corresponding basically
to the catalytic domain alone had higher autophosphorylation
activity; our data suggest that the very COOH-terminal region
of the protein contributes to this regulation.
CDKL5 Is Capable of Phosphorylating the TEY Motif in Its
Activation Loop—CDKL5 contains theTEY sequencewithin its
activation loop (residues 169–171); this motif has been exten-
sively characterized in the extracellular signal-regulated
kinases (ERKs), and its dual phosphorylation is required for
activation of these protein kinases (14). Thismechanismof acti-
vation is in most cases mediated by other upstream kinases;
however, one member of the ERK family, ERK7, has been
shown to be constitutively active due to its ability to autophos-
phorylate the TEY motif (15). CDKL5 has previously been
reported to be phosphorylated on its TEY motif; in fact, the
anti-phospho-MAPK antibody recognizes overexpressed
CDKL5 immunopurified from mammalian cells (11). We
wanted to investigate whether an altered autophosphorylation
activity could affect the modification of the TEY motif. To this
aim, we performed a Western blot analysis of the various
FLAG-tagged immunopurified CDKL5 derivatives with the
anti-phosphoMAPKantibody (Fig. 3A,upper panel). 15% of the
immunoprecipitated material was analyzed with an anti-
CDKL5 antibody to assay the amount of immunopurified
CDKL5 (Fig. 3A, lower panel). As illustrated in Fig. 3A, wild-
type CDKL5 is recognized in this assay, confirming that it is
indeed phosphorylated on its TEY motif (lane 2). The CDKL5
FIGURE 2. Two disease-causing mutations within the catalytic domain
interfere differently with CDKL5 autocatalytic activity. A, autophospho-
rylation assay in which FLAG-CDKL5 and its mutated derivatives were immu-
nopurified from overexpressing HEK293 cells and, after extensive washes,
incubated with ["-33P]ATP for 30 min at 30 °C. Labeled proteins were divided
in two fractions; 85% was separated by SDS-PAGE and visualized by autora-
diography (upper panel),whereas the remaining15%were subjected toWest-
ern blot analysis with anti-CDKL5 antibodies (lower panel). Molecular masses
are indicated to the left. B, graphic illustration showing the quantitation of
CDKL5 autophosphorylation activity from three independent experiments.
The data show the ratio of the radioactive signal (quantified with a Phospho-
rImager) to the amount of immunoreactive proteins (estimated with a Kodak
ImageStation2000R) for eachCDKL5derivative. CDKL5autophosphorylation
activity was arbitrarily set to 1.0 and the activity of its mutated derivatives
expressed as values relative to this.
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derivative lacking the region spanning the 249 most COOH-
terminal amino acids is also phosphorylated (lane 3), whereas
the kinase-dead mutant, K42R, is not immunoreactive with the
anti-phosphoMAPK antibody (data not shown). In accordance
with the autophosphorylation data, we observed that while the
C152Fmutant was not recognized at all (lane 5), R175Swas less
reactive in theWestern blot (lane 4) even if the analysis with the
anti-CDKL5 antibody shows that comparable amounts of pro-
teinwas immunopurified in all lanes. The graphic illustration in
Fig. 3B, obtained normalizing the results of three independent
experiments, confirms that indeed the Rett 175missensemuta-
tion leads to a hypoactive CDKL5 protein, whereas the !781
truncation has exactly the opposite effect making the enzyme
more effective. Moreover, these experiments show a correla-
tion between the ability to autophosphorylate and to be phos-
phorylated on the TEYmotif suggesting that CDKL5 is capable
of autoactivating by modifying the dual phosphorylation site
within the activation loop. These results, however, do not reveal
if this is an intermolecular autophosphorylation or if it occurs in
cis. We examined this point by investigating whether the
kinase-dead mutant, K42R, might be TEY-phosphorylated
when overexpressed in the presence of wild-type CDKL5. To
this aim, K42R fused to the green fluorescent protein, GFP, was
overexpressed together with FLAG-
CDKL5 or, as a negative control,
FLAG alone. The extracted proteins
were immunopurified with anti-
GFP and analyzed with anti-phos-
phoMAPK antibodies. Interest-
ingly, as demonstrated in Fig. 3C,
GFP-K42R was recognized by the
anti-phophoMAPK antibody when
it was immunopurified from cells
overexpressing also the wild-type
FLAG-tagged protein but not FLAG
alone (lanes 6 and 5, respectively).
The specificity was confirmed by
the fact that no signal was present
when only GFP was expressed with
FLAG-CDKL5 (lane 4). This result
allows us to establish that CDKL5 is
indeed capable of phosphorylating
its own TEY motif and the fact that
the phosphorylation in this experi-
ment occurs in trans implies that
CDKL5 interacts with itself, either
directly or indirectly. This point was
addressed by assaying if GFP-
CDKL5 coprecipitated with immu-
nopurified FLAG-CDKL5. As dem-
onstrated in Fig. 3D, GFP-CDKL5
was indeed present in the material
that coimmunopurifiedwith FLAG-
CDKL5 (lane 4) confirming that
CDKL5 is able to phosphorylate in
trans because the molecules are
contacting each other; whether
CDKL5 is also able to cis-phospho-
rylate as suggested by Lin et al. (11) cannot be excluded from
these data. Eventually, we observed that kinase dead CDKL5
molecules are able to interact suggesting that TEY phosphoryl-
ation is not required for this property; in fact, GFP-K42R and
FLAG-K42R coprecipitate (data not shown).
MeCP2 Phosphorylation Is Impaired in Two Disease-causing
Mutations within the Catalytic Domain—We have previously
shown that immunopurified CDKL5 mediates the phosphoryl-
ation, directly or indirectly, of MeCP2 (8), and presently this
remains the only heterologous substrate of CDKL5.Wewanted
to test the impact of the various mutations in CDKL5 on its
capacity to mediate MeCP2 phosphorylation; in particular, we
found it challenging to analyze if the hypomorphic R175S
mutantmight be defective in phosphorylating themethyl-bind-
ing protein. To this aim, recombinant purified MeCP2E2 was
incubated with immunopurified FLAG-tagged CDKL5 or its
mutated derivatives in the presence of ["-33P]ATP. Labeled
proteins were separated by SDS-PAGE and visualized by auto-
radiography. As described above (Fig. 2), CDKL5 and MeCP2
amounts were detected byWestern blot. As seen in the autora-
diogram in Fig. 4, MeCP2 is readily phosphorylated in the pres-
ence of wild-type CDKL5 (lane 4), whereas no signal is present
when the methyl-binding protein is incubated with the resin
FIGURE 3. Phosphorylation of the TEY motif correlates with the autocatalytic activity of CDKL5 and is
mediated by intermolecular phosphoryation. A, phosphorylation of the TEY motif was analyzed subjecting
immunopurified FLAG-CDKL5 or its mutated derivatives to Western blot with anti-phospho-MAPK antibodies
(upper panel). 15% of the immunoprecipitated material was analyzed by Western blot with anti-CDKL5 anti-
bodies (lower panel). Molecular masses are indicated to the left. B, graphic illustration showing the mean
relative TEY-phosphorylation from three individual experiments. The amounts of TEY-phosphorylation and
immunopurified CDKL5 were quantified with a Kodak Image Station 2000R. TEY phosphorylation of wild-type
CDKL5 was arbitrarily set to 1.0 and the degree of phosphorylation of its mutated derivatives expressed as
values relative to this. C, autophosphorylation of the TEY motif was examined by coexpressing GFP-K42R or
GFP with FLAG-CDKL5 or FLAG in HEK293 cells, immunopurifying the proteins with anti-GFP and anlyzing the
precipitated material with anti-P-MAPK (upper panel) or anti-CDKL5 antibodies (lower panel). Lanes 1–3 and
lanes 4–6 show the input and immunoprecipitate, respectively. D, CDKL5 autointeraction was analyzed by
coimmunopurification of GFP-CDKL5 and FLAG-CDKL5 from overexpressing HEK293 cells. Overexpressed pro-
teins were purified with an anti-FLAG resin and analyzed with anti-CDKL5. The upper panel shows the input
whereas the precipitated material is shown in the lower panel. Molecular masses are indicated to the left.
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containing only FLAG or the kinase dead controls, !N and
K42R (lanes 2, 6, and 14, respectively). The !781 derivative has
maintained its MeCP2 interaction domain, which is located
between amino acids 450–550. Accordingly, as can be seen in
Fig. 4, !781 is capable of mediating MeCP2 phosphorylation
(lane 8). On the contrary, the two missense mutations in the
catalytic domain, C152F and R175S, are impaired in phospho-
rylating MeCP2. This means that in our experimental condi-
tions theR175Smutant is unable tomediate themodification of
MeCP2, even if it is characterized by a low autocatalytic activity
and TEY phosphorylation. As expected, the C152F mutant,
devoid of autocatalytic activity, does not induce any modifica-
tion of MeCP2.
TheCDKL5COOH-terminal Region Is Important for a Proper
Subcellular Localization—The lowered catalytic activity of
mutations within the NH2-terminal kinase domain can provide
an explanation for disease onset in patients. Conversely, the
COOH-terminal truncation ofCDKL5 represented by the!781
derivative, which is a Rett causing mutation mapping in the
region often mutated in patients with mental retardation and
infantile spasms, showed better performance in our autophos-
phorylation assays. Even though it is possible to speculate that a
higher catalytic activity might be detrimental for brain func-
tion, we wanted to analyze if this region or the catalytic activity
are important for other regulatory aspects of the protein such as
its subcellular localization. To this aim, we compared the sub-
cellular distribution of the various overexpressedCDKL5deriv-
atives fused to GFP in mouse fibroblasts, NIH3T3, and human
HEK293 cells. Fig. 5A shows a typical localization pattern of
each CDKL5 derivative inNIH3T3 cells (GFP, upper row,A–G)
where the cell nucleus was identified with Hoechst staining
(Hoechst,middle row,A$–G$).Wild-type CDKL5 was predom-
inantly nuclear with a particular dotted staining (A; Ref. 11).
Even if the nature of these dots remains unknown, it appears
from the lack of overlap between GFP andHoechst (merge, lower
row,A%–G%) that they donot correspond to the intenselyHoechst-
stainedpericentric foci rich inmethy-
lated DNA and MeCP2 (16). We ob-
served, however, that these nuclear
dots appeared bigger in size when the
protein was heavily overexpressed,
and we have therefore paid attention
on assaying cells expressing the exog-
enous proteins only at moderate lev-
els. The same nuclear dotted staining
was also observed with the !781 and
R175S derivatives (B and E, respec-
tively) and also in few cells expressing
theC152Fmutant ("25%;D). On the
contrary the kinase-dead K42R mu-
tant and in large part the Rett C152F
derivative were characterized by the
complete lack of nuclear dots; a simi-
lar result was obtained with the !525
mutant. Furthermore, we noticed
that !525, C152F, and K42R had
some cytoplasmic staining. There is a
significant difference between the
!781 and !525 derivatives; in fact, the !781 mutant behaves like
the wild-type protein, whereas the !525 mutant has completely
lost the dotted staining and localizes partially within the cyto-
plasm. This suggests that theCOOH-terminal region plays an im-
portant role in localizing the kinase properly within the nuclear
compartment, possibly by its interaction with other nuclear fac-
tors. It is worthwhile mentioning that identical results were ob-
tained in human HEK293 cells, where the heterochromatic dots
are not identifiable with Hoechst staining (data not shown).
Since our data suggest that both the catalytic activity of
CDKL5 and residues comprised between 526 and 780 might
regulate the localization of the kinase within the nucleus, we
decided to investigate this point further and performed aWest-
ern blot analysis using fractionated cell extracts. We therefore
compared the full-length CDKL5 derivatives as well as the
COOH-terminal deletions, !781 and !525. As seen in Fig. 5B,
wild-type CDKL5, !781, and R175S are found predominantly
in the nuclear fraction (lanes 3, 6, and 15, respectively), whereas
the !525 as well as the C152F and K42R mutants were present
also in the cytoplasmic fractions (lanes 8, 11, and 17, respec-
tively). A good correlation thus exists between the immunoflu-
orescence and Western blot analysis and the obtained results
indicate that the nucleocytoplasmic distribution ofCDKL5may
indeed depend on the catalytic activity of the kinase and
sequences within its COOH-terminal domain; we cannot
exclude the opposite situation, however, that the nuclear trans-
location depends on a correct domain configuration and is
important for CDKL5 catalytic activity.
DISCUSSION
The human CDKL5 gene has been mapped to Xp22 through
an exon trapping screening aimed at identifying novel genes
associated with human disorders (1). Indeed, several recent
publications reported the involvement of CDKL5 in some neu-
rodevelopmental disorders, and mutations in CDKL5 have
been isolated from patients affected by West Syndrome, the
FIGURE 4. Disease-causing mutations within the CDKL5 kinase domain interfere with MeCP2 phospho-
rylation. Immobilized FLAG-CDKL5, or its mutated derivatives, was incubated with or without recombinant
MeCP2 and ["-33P]ATP for 30 min at 30 °C. Labeled proteins were divided in two fractions; 85% were separated
by SDS-PAGE and visualized by autoradiography (upper panel), while the remaining 15% was subjected to
Western blot analysis with anti-CDKL5 (middle panel) or anti-MeCP2 antibodies (lower panel). The position of
phosphorylated CDKL5 derivatives and MeCP2 in the upper panel is indicated to the right. Molecular mass
markers are indicated to the left. Recombinant MeCP2 was added to lanes 2, 4, 6, 8, 10, 12, and 14.
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Hanefeld variant of Rett Syndrome, and Infantile Spasms (2–9).
Integrating all the data,CDKL5 seems to be an important cause
in females of clinical manifestations characterized by severe
mental retardation and seizures starting within the first 6
months of life and largely resistant to treatment. According to
its involvement in brain function, CDKL5 is a ubiquitous pro-
tein particularly expressed in the brain (1, 11). Moreover, stud-
ies on Cdkl5 activation during brain development have shown
that its transcription is first observed in neural cells that have
reached their final position in the cortical plate. In the first
postnatal stages its expression correlates with neuronal matu-
ration and synaptogenesis (8).
The analysis of the primary sequence of CDKL5 revealed
homologies with the catalytic domain of different members of
proline directed serine-threonine kinases (1). In fact, it has
recently been demonstrated that CDKL5 owns a phospho-
rylating activity (8, 11). In analogy to all the other members of
the family of ser/thr kinases, 12 conserved subdomains can be
identified in the 284-amino acid kinase domain of CDKL5 (12).
Interestingly, most of the pathogenic missensemutations iden-
tified so far hit the catalytic domain suggesting that the enzy-
matic activity is required for a normal neurodevelopment. In
this paper we have compared the activity of wild-type CDKL5
to that of two point mutants causing a variant form of Rett.
Cysteine 152, located immediately upstream the conserved
DFG motif involved in phosphotransfer, has been substituted
with phenylalanine (4, 12). Tao and colleagues (4) have recently
observed that there are no other deposited sequences charac-
terized by a phenylalanine residue in this position and proposed
that this mutation might modify the proper orientation of the
DFG signature important for a proper catalytic activity. In our
assays of auto- and heterophosphorylation this Rett derivative
does not show any catalytic activity (Figs. 2 and 4, respectively).
Furthermore, the immunoprecipitated C152F mutant is not
recognized by the antibody specific for the activated TEY (Fig.
3). Therefore, in these assays, this mutant behaves as the K42R
that, by definition, is a kinase-dead protein. However, the com-
parison of the cellular distribution of this mutant with the
“dead” derivative revealed some differences (Fig. 5). In fact,
microscopy and biochemical assays show that wild-type
CDKL5 is characterized by a nuclear dotted staining and
remains almost undetectable in the cytoplasm.On the contrary,
the kinase dead mutant discloses an almost equal distribution
between the nucleus and the cytoplasm; concerning the sub-
nuclear distribution, the exogenous protein has lost the punc-
tuated pattern. Interestingly, the C152F mutant appears as an
intermediate between the wild-type and the K42R mutant; in
fact, whereas"25% of the cells show a dotted nuclear staining,
almost 75% present a diffuse distribution of the mutated
CDKL5. Eventually, a weak signal is detectable in the cyto-
plasm. With this in mind, we suggest that a correct subcellular
distribution of this kinase requires a threshold catalytic activity
and that the C152F mutant retains some residual phospho-
rylating activity that, even if too weak to be detected in our
enzymatic assays, is testified by its distribution in the cell. We
have also analyzed the R175S Rett mutation that, considering
FIGURE 5. CDKL5 subcellular localization is influenced by its catalytic activity and protein-protein interactions. A, CDKL5 and its mutated derivatives
were fused to GFP and transiently overexpressed in NIH3T3 cells. Fixed cells were stained with Hoechst and the subcellular localization of the exogenous
protein analyzed. Theupper row showsGFP-expressingcells (A–G), themiddle row shows theHoechst stainednuclei (A$–G$), and the lower row shows themerge
with GFP in green and Hoechst in blue (A%–G%). B, Western blot of fractionated HEK293 cells overexpressing GFP-tagged CDKL5 or its mutated derivatives
analyzed by anti-CDKL5. T& total extract; n& nuclear extract, C& cytoplasmic extract.
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its autophsphorylation (Fig. 2) and TEY modification (Fig. 3),
appears active but hypomorphic. In accordance with our
model, its cellular distribution appears indistinguishable from
the wild-type CDKL5 (Fig. 5) reinforcing the hypothesis that a
certain catalytic activity is required for the nuclear localization.
The mutated Arg-175 lies within a highly conserved sequence
context important for the recognition of substrates containing a
proline immediately after the Thr/Ser residue acceptor of the
phosphate (17, 18). It has been hypothesized that the R175S mu-
tation might change substrate specificity (4). Our data seem to
confirm this; in fact, the R175S derivative is unable to mediate
MeCP2modification even though it is capable of interacting with
themethyl-binding protein (Fig. 4 anddata not shown).Although,
so far, there are no proofs of the capability of CDKL5 to directly
modify themethyl-bindingprotein,our results suggest that invitro
the immunopurified kinase is capable of doing so, therefore
strengthening their belonging to the same molecular path-
way (Fig. 4 and Ref. 8). Linking the obtained data to Rett
syndrome, it appears that impairment of the kinase activity
and/or of its substrate specificity might be pathogenic.
Moreover, analyzing the phenotype of the patients described
by Tao and colleagues (4) we can speculate that a correlation
exists between the severity of the neurological disorder and the
degree of the catalytic impairment. Eventually, we are aware
that Lin et al. (11) have recently published that the twomissense
mutations lead to a completely inactive enzyme. However, the
authors have analyzed themutated derivatives in the context of
a 352-residue peptide, missing all the amino acids COOH-
terminal to the kinase domain.We believe that this, as well as a
difference in the sensitivity of the assays, might justify the ap-
parent contradictory results. Other two missense mutations
have been described (Fig. 1). The first, I72N, causing Rett syn-
drome, consists in the substitution of an isoleucine residuewith
an asparagine; interestingly, this isoleucine is strictly main-
tained in CDKL5 and has a conservative substitution into
leucine in other CDKL family members (7). The second muta-
tion, responsible for severe mental retardation, marked hypo-
tonia, and serious epileptic seizures, leads to the substitution of
a highly conserved proline residue (P180L). In the future, it will
be interesting to analyze the molecular consequences of these
alterations.
As already mentioned, truncating mutations have also been
reported (5–8). While it is easy to understand the pathogenic
effects of mutations terminating the protein in the NH2-termi-
nal end, therefore abolishing the kinase activity, it is not known
what the consequences are of later truncations that terminate
the protein in the long, still uncharacterized COOH-terminal
region.Wehave therefore decided to analyze amutation, which
causes the truncation of CDKL5 at R781 and causes the
Hanefeld variant of Rett syndrome (8). It is worthwhile to note
that this is one of the earliest COOH-terminal truncations
reported so far. As for the other mutants, the !781 derivative
has been challenged in auto- and heterophosphorylation assays
(Figs. 2–4) and the obtained results suggest that the protein has
a slightly augmented catalytic activity. Since the cellular distri-
bution of this mutant resembles that of the wild-type protein,
and we do not observe a reproducible higher expression (data
not shown) we suggest that, in this case, the neurological dis-
ease might be explained by the hyperactivity of the kinase. A
possible confirmation of this working hypothesis with future
experiments might suggest that a tight regulation of CDKL5
levels and/or activity is essential for the proper function of the
central nervous system therefore making the search for patho-
genic gene duplications relevant. In line with this, it is worth
mentioning that also MeCP2 protein levels need to be strictly
regulated to maintain proper brain functions; in fact, male Rett
patients withMECP2 gene duplications have been described in
accordancewith the observation that toomuchMeCP2 protein
causes Rett like phenotypes in mice (19). Moreover, the identi-
fication of the physiological targets of CDKL5 will permit us to
disclose if a hypermorphicmutant is capable ofmodifying novel
proteins or if it is responsible for an excess of activity on correct
substrates. We want to mention that even if this is just a work-
ing hypothesis, it has already been published that a hyperactiv-
ity of protein kinases, such as CDK5, might lead to neuronal
pathologies (20). However, we cannot exclude that the molec-
ular cause of this pathogenic mutation resides in protein-pro-
tein interactions defects.
Albeit CDKL5 remains largely uncharacterized, our data
together with two previous publications (8, 11) provide addi-
tional information about CDKL5 functional domains and reg-
ulation. In particular, we have demonstrated that CDKL5 is
capable of associating with itself and that this interaction
occurs independently of an active catalytic domain (Fig. 3 and
data not shown). Conversely, we still do not know if this inter-
action is direct or mediated through a yet unknown factor. The
activation loop of CDKL5 contains a TEY motif whose phos-
phorylation seems to be required for the kinase activity (Ref. 11
and this paper). Exogenously expressed CDKL5 leads to an
intermolecular autophosphorylation of this activating signa-
ture (Fig. 3); to our knowledge, the capability of autoactivating
the TEY motif has, so far, only been described for ERK7 (21).
CDKL5 is a rather big kinase due to a remarkably large
COOH-terminal extension of almost 700 amino acids that har-
bors several functions. First, the tail seems to act as a negative
regulator of the catalytic activity of CDKL5 (11), and our results
suggest that this function is enclosed in the very last 240 resi-
dues (Figs. 2–4). Interestingly, also the long COOH-terminal
extension of ERK5 stabilizes it in an inactive form and this
occurs through the phosphorylation of a serine residue (22).
Moreover, a region of CDKL5 encompassing residues 526–780
is necessary for the subnuclear localization. In fact, whereas the
wild-type protein as well as the !781 derivative show a typical
speckled staining, a further truncation at amino acid 525 leads
to a diffuse staining (Fig. 5); we suggest that thismutant has lost
a region important for protein-protein interactions. Impor-
tantly, analyzing the primary structure of the protein (Fig. 1A) it
appears that the !525 mutants lacks three of the four Src
homology 3-binding sites. Furthermore studies will define
which and how many other regulatory functions are carried
out by the COOH-terminal domain. Eventually, as already
mentioned, regarding the CDKL5 subcellular localization
our working model is that its entry into the nucleus depends
on its kinase activity; however, in analogy with ERK7, its
permanence in this cellular compartment depends on spe-
cific protein-protein interactions.
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